via University of Sheffield
Scientists from the University of Sheffield have discovered MRI scanners, normally used to produce images, can steer cell-based, tumour busting therapies to specific target sites in the body.
Magnetic resonance imaging (MRI) scanners have been used since the 1980s to take detailed images inside the body – helping doctors to make a medical diagnosis and investigate the staging of a disease.
An international team of researchers, led by Dr Munitta Muthana from the University of Sheffield’s Department of Oncology, have now found MRI scanners can non-invasively steer cells, which have been injected with tiny super-paramagnetic iron oxide nanoparticles (SPIOs), to both primary and secondary tumour sites within the body.
This targeted approach is extremely beneficial for patients as it dramatically increases the efficiency of treatment and drug doses could potentially be reduced – helping to alleviate side effects.
Revolutionary cell-based therapies, which exploit modified human cells to treat diseases such as cancer, have advanced greatly over recent years. However, targeted application of cell-based therapy in specific tissues, such as those lying deep in the body where injection is not possible, has remained problematic.
The new research suggests MRI scanners are the key to administering treatments directly to both primary and secondary tumours wherever they are located in the body.
The study, published today (date) in Nature Communications shows that cancer mouse models injected with immune cells carrying SPIOs and armed with the cancer killing oncolytic virus (OV) which infects and kills cancer cells, showed an 800 per cent increase in the effects of the therapy.
Dr Munitta Muthana, from the University of Sheffield, said: “Our results suggest that it is possible to use a standard MRI scanner to naturally deliver cell-based therapies to both primary and secondary tumours which would normally be impossible to reach by injection.
“This not only increases the therapeutic efficacy but also decreases the risk of unwanted side effects.
“The beauty of using the MRI scanner to administer the therapy is that you can also use it for its original purpose providing a real-time image-guide to ensure the treatment has gone where it is needed.”
Read more: MRI scanners can steer tumour busting viruses to specific target sites within the body
The Latest on: Tumour busting therapies
via Google News
The Latest on: Tumour busting therapies
- New guideline refines care for brain bleeds: Compression socks, some meds not effectiveon May 17, 2022 at 2:36 am
Some treatments or preventive therapies used to manage intracerebral hemorrhages (ICH), or a bleeding stroke, are not as effective as previously believed, according to the new American Heart ...
- Study identifies barriers for women returning to work after breast canceron May 11, 2022 at 9:46 am
Occupational therapy researchers find women living with and beyond breast cancer in Ireland are not aware of their employment entitlements and in response to findings have developed the occupational ...
- OSE Immunotherapeutics To Present at ‘Immuno-Oncology Summit Europe’ and at ‘Tumor Myeloid-Directed Therapies Summit’ In London and Bostonon May 11, 2022 at 9:08 am
Presentations to focus on CLEC-1, novel myeloid immune checkpoint target for cancer immunotherapy NANTES ... from Target Validation to Clinical Translation Tumor Myeloid-Directed Therapies Summit June ...
- Strata Oncology Enrolls First Patient in Strata PATH Trial Investigating New Pan-Tumor Indications for Approved Cancer Therapieson May 11, 2022 at 6:07 am
Strata Oncology, Inc., a next-generation precision oncology company enabling smarter and earlier cancer treatment, today announced enrollment of the first patient in the Strata P recision Indications ...
- T-Cell Behavior in Tumors Affects Immunotherapy Response, Predicts Patient Survivalon May 11, 2022 at 5:00 am
Study results overturn the prevailing model of immune responses in melanoma and point to different therapeutic approaches.
- Moma’s moment comes with a $150M series B to target solid tumorson May 9, 2022 at 5:00 pm
With a 2020 launch behind it, Moma Therapeutics Inc. has completed a $150 series B financing to continue refining its pipeline of therapies targeting tough-to-drug enzymes in treating solid tumors.
- Immunotherapy for Melanomaon May 8, 2022 at 5:00 pm
This "second generation version" of immunotherapy works by increasing the number of cancer-busting T-cells ... with chimeric antigen receptor T-cell therapy, or CAR-T, in treating lymphoma ...
- Interview With Donald E Ingberon May 6, 2022 at 5:00 pm
Q Your Recent Publications in Nanomedicine Have Been on a Variety of Topics, Including Cancer Therapy and Thrombosis ... There are great clot-busting drugs out there, such as tissue plasminogen ...
- Global PARP Inhibitors Cancer Therapy Market Trends Size Drug Sales insight 2028on May 4, 2022 at 11:41 pm
Singapore, May 05, 2022 (GLOBE NEWSWIRE) -- Global PARP Inhibitors Cancer Therapy Market & Clinical Trials Insight 2028 Report Highlights: Global PARP Inhibitors Cancer Therapy Market opportunity: > ...
- What Is Sex Therapy Actually Like?on May 4, 2022 at 4:29 pm
Despite what people may think, if you have sex, have had sex, want to have sex, or think about sex, it's likely you could benefit from sex therapy. In other words, sex therapy isn't "just" for those ...
via Bing News
One Comment
Thomas Prevenslik
MRI to direct nanoparticles (NPs) to a cancer cell is a great idea. It may be simpler and economically better to intravenously inject biodegradable 80 nm NPs in to the blood stream, the NPs sized to emit low levels of UV, the UV killing the cancer by damaging the reproductive DNA of the cancer. With patients tested positive for Covid-19, the virus is killed in vivo and the killed virus acts as the antigen to elict immunity. See the “Nanoparticle Treatment” at nanoQED.org , 2020.